This study therefore discusses the cell cycle’s molecular mechanisms as well as the dysregulation in cancer, CDK structures, and drug complexes, as along with selected CDK inhibitors, including FDA-approved and currently undergoing clinical trial CDK4/CDK6 inhibitors. This evidence concerns the gene CDK6 and cancer.